Showing 341-350 of 1560 results for "".
Expanding Cancer Detection: How MCED Testing Complements Standard Screening
https://reachmd.com/programs/project-oncology/expanding-cancer-detection-how-mced-testing-complements-standard-screening/28652/Current cancer screening guidelines cover just five cancers—breast, lung, colon, prostate, and cervical—leaving many aggressive cancers undetected until later stages. But multi-cancer early detection (MCED) testing is reshaping the landscape with blood-based analyses of cell-free DNA and methylationDialogue with the Experts: Best Practices in NSCLC
https://reachmd.com/programs/project-oncology/dialogue-with-the-experts-best-practices-in-nsclc/9626/Lung Cancer is the leading cause of cancer death and the second most diagnosed cancer in both men and women in the US. Incidence rates vary from state to state, but are of concern in the South.1 These sobering statistics are compounded by the documented variations in non-small-cell lung cancer (NSCEvolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
https://reachmd.com/programs/deep-breaths-updates-chest/evolving-strategies-in-resectable-nsclc-insights-from-asco-and-astro-2025/35982/Recent data from ASCO and ASTRO 2025 are redefining standards of care for resectable non-small cell lung cancer (NSCLC). Drs. Gerard Silvestri, Mariam Alexander, Anurag Singh, and Jessica Donington review these updates on the importance of molecular testing, careful surgical selection, and multidiscOptimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
https://reachmd.com/programs/deep-breaths-updates-chest/optimizing-treatment-pathways-in-nsclc-the-role-of-the-multidisciplinary-team/35981/Effective care for non-small cell lung cancer (NSCLC) now depends on early molecular testing and coordinated input from a variety of specialties. Dr. Gerard Silvestri sits down with Drs. Jessica Donington, Mariam Alexander, and Anurag Singh to review why multidisciplinary integration is critical toThe CellFX System from Pulse Biosciences
https://modernaesthetics.com/topics/energy-based-devices/the-cellfx-system-from-pulse-biosciences/35181/PRP Scaffolds in Chronic Wound Care: A Move Toward Regenerative Solutions
https://reachmd.com/programs/clinicians-roundtable/prp-scaffolds-in-chronic-wound-care-a-move-toward-regenerative-solutions/36422/Rethinking Anti-Aging
https://modernaesthetics.com/topics/regenerative-medicine/rethinking-anti-aging/48724/Cellular longevity and the role of mTOR in skin health.Generating More Than Buzz
https://modernaesthetics.com/topics/practice-development/generating-more-than-buzz/35419/Pioneers in the field share key information at Genesis: Innovations in Aesthetic Regenerative MedicineCellular Vaccine Development as Cancer Therapy
https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/cellular-vaccine-development-as-cancer-therapy/4595/What are cellular vaccines and how do they differ from what we think of as conventional vaccines? What are the various types of approaches that we can potentially use for inducing anti-cancer immunity? Dr. Don Siegel, vice chair and professor of pathology and laboratory medicine at Penn Medicine, taNew Recommendations for STEMI and PCI
https://reachmd.com/programs/heart-matters/new-recommendations-for-stemi-and-pci/4962/What are the 2009 recommendations for best managing ST-segment-elevation myocardial infarction, or STEMI, and the need for percutaneous coronary intervention, or PCI? Dr. Judith Hochman, the Harold Snyder Family Professor of Cardiology and clinical chief of cardiology at the New York University (NYU